MetaCap

20/20 Biolabs Inc. (AIDX)

NASDAQ: AIDXHealth CarePrecision InstrumentsUSD

0.1571-0.0245 (-13.49%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AIDX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.75
52-week range
0.1556 – 50.00
Day range
0.1556 – 0.1803
Volume / Avg
301.48K / 139.24K
Beta
—

52-week range

$0.1556$50.00

AIDX stock today

On Nov 20, AIDX ended the session at $0.1571, shedding $0.0245 (13.49%), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 301.48K shares, a sign of unusually heavy trading. At this level, AIDX sits near the bottom of its 52-week range of $0.1556 to $50.00: 99.7% below the high and 1.0% above the low.

20/20 Biolabs has posted a net loss over the last twelve months (EPS of -$0.75), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About 20/20 Biolabs

Company profile

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers.

Industry
Precision Instruments
CEO
Mr. Jonathan Cohen
Headquarters
Gaithersburg, MD
Employees
4

Financial highlights

Full financials

In fiscal 2025, 20/20 Biolabs generated $2.0 million in revenue, up 16.7% from fiscal 2024. 20/20 Biolabs reported a net loss of $3.7 million, compared with a loss of $5.6 million a year earlier. Gross margin was 29.6% (up from 20.6%) and operating margin -162.9%.

20/20 Biolabs annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$2.05M$1.75M
Growth+16.71%—
Net income$-3.74M$-5.55M
EPS (diluted)$-0.76$-1.16

Analyst forecast

Forecast

Consensus

none

Avg. price target

$5.00+3082.69%

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.12 vs —

AIDX news

All AIDX news

20/20 Biolabs peers

Health Care sector
AIDX peer companies
CompanyPrice% ChgMarket capCompare
NEONeoGenomics Inc.14.82-1.79%$1.92Bvs AIDX
ULSUL Solutions Inc. Class A72.64-2.99%$14.67Bvs AIDX

Indexes, lists and sector

20/20 Biolabs stock FAQ

What is 20/20 Biolabs's stock price today?

AIDX last traded at $0.1571 as of Nov 20, 4:00 PM EST, down 13.49% on the day. Prices are delayed at least 15 minutes.

Who is 20/20 Biolabs's CEO?

Mr. Jonathan Cohen is the chief executive officer of 20/20 Biolabs Inc., which has about 4 employees.

What is the AIDX 52-week high?

The 52-week high for AIDX is $50.00 and the 52-week low is $0.1556. The stock is currently 99.7% below its high.

Compare AIDX